Edition:
United States

Aduro Biotech Inc (ADRO.OQ)

ADRO.OQ on NASDAQ Stock Exchange Global Select Market

8.00USD
11:22am EDT
Change (% chg)

$0.05 (+0.63%)
Prev Close
$7.95
Open
$7.95
Day's High
$8.05
Day's Low
$7.95
Volume
9,508
Avg. Vol
118,624
52-wk High
$14.00
52-wk Low
$5.85

Latest Key Developments (Source: Significant Developments)

Aduro Biotech Q4 Loss Per Share $0.34
Thursday, 1 Mar 2018 04:01pm EST 

March 1 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 REVENUE $3.8 MILLION VERSUS $3.9 MILLION.Q4 LOSS PER SHARE $0.34.  Full Article

Aduro Biotech Announces Management Changes
Friday, 5 Jan 2018 08:00am EST 

Jan 5 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH INC - JENNIFER LEW HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER.ADURO BIOTECH ANNOUNCES MANAGEMENT CHANGES.ADURO BIOTECH - GREGORY SCHAFER WILL BE STEPPING DOWN AS CHIEF OPERATING OFFICER IN EARLY MARCH.  Full Article

Aduro Biotech Provides Update On CRS-207 Programs
Tuesday, 12 Dec 2017 08:00am EST 

Dec 12 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH PROVIDES UPDATE ON CRS-207 PROGRAMS.COMPANY HAS DETERMINED THAT IT WILL NOT CONTINUE ADVANCEMENT OF CRS-207.COMPANY WILL WIND DOWN EACH OF ITS TRIALS IN MESOTHELIOMA, OVARIAN AND GASTRIC CANCER FOR CRS-207.EXPECT CURRENT CASH BALANCE TO BE SUFFICIENT TO FUND PLANNED ACTIVITIES FOR NEXT THREE YEARS THROUGH 2020.  Full Article

Aduro Biotech reports Q3 loss per share $0.33
Tuesday, 31 Oct 2017 04:01pm EDT 

Oct 31 (Reuters) - Aduro Biotech Inc ::Aduro Biotech reports third quarter 2017 financial results.Q3 loss per share $0.33.Q3 revenue $3.8 million versus $3.8 million.Q3 revenue view $6.1 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S.Aduro Biotech Inc - ‍ anticipated 2017 milestones include to initiate phase 1 multiple myeloma trial with bion-1301, an anti-April antibody​.  Full Article

Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD
Wednesday, 27 Sep 2017 08:01am EDT 

Sept 27 (Reuters) - Aduro Biotech Inc :Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD based on proprietary neoantigen technology.Aduro Biotech Inc - ‍trial is seeking to enroll approximately 10 patients with metastatic colorectal cancer that is MSS​.  Full Article

Aduro Biotech files for resale of up to 25.41 mln shares of common stock by the selling stockholders‍​
Wednesday, 2 Aug 2017 05:51pm EDT 

Aug 2 (Reuters) - Aduro Biotech Inc ::Aduro Biotech Inc files for resale of up to 25.41 million shares of co's common stock by the selling stockholders‍​ - sec filing.  Full Article

Aduro Biotech files for mixed shelf of upto $300 mln
Wednesday, 2 Aug 2017 05:27pm EDT 

Aug 2 (Reuters) - Aduro Biotech Inc ::Aduro Biotech Inc files for mixed shelf of upto $300 million - sec filing.  Full Article

Aduro Biotech Q2 loss per share $0.27
Wednesday, 2 Aug 2017 04:01pm EDT 

Aug 2 (Reuters) - Aduro Biotech Inc :Aduro Biotech reports second quarter 2017 financial results.Q2 loss per share $0.27.Q2 revenue $5.9 million versus $39 million.Q2 revenue view $11.2 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.  Full Article

Aduro Biotech reports $2 mln milestone payment under licensing deal with Merck
Thursday, 13 Jul 2017 08:00am EDT 

July 13 (Reuters) - Aduro Biotech Inc :‍​:Aduro Biotech- $2.0 million milestone payment under worldwide licensing deal with merck for work supporting preparation of ind for anti-cd27 antibody​.‍Aduro announces milestone achieved relating to collaboration with merck for development of anti-cd27 antibody for treatment of cancer​.  Full Article

Aduro Biotech announces first patient dosed in phase 2 clinical trial of crs-207 in combination with keytruda
Wednesday, 28 Jun 2017 04:05pm EDT 

June 28 (Reuters) - Aduro Biotech Inc :Aduro Biotech announces first patient dosed in phase 2 clinical trial of crs-207 in combination with keytruda® (pembrolizumab) for the treatment of patients with previously treated malignant pleural mesothelioma.  Full Article

BRIEF-Aduro Biotech Q1 Loss Per Share $0.28

* Q1 EARNINGS PER SHARE VIEW $-0.35 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage: